Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Egypt sole reporter of steady stream of H5N1 avian flu cases

This article was originally published in Clinica

Executive Summary

With two new cases of H5N1 avian flu confirmed in late November, Egypt remains the only country to have reported human infections of the virus since Vietnam announced a fatal case in early May, according to data broadcast by the World Health Organization (WHO). Egypt's Central Public Health Laboratories have reported a steady stream of 21 cases and four deaths since then. They bring the number of cases in the country this year to 38, with four deaths. In contrast with this unusually high survival rate for H5N1, the four cases reported by Vietnam this year were all fatal. The only other country to have reported cases in 2009 is China, with seven cases and four deaths. The global WHO-confirmed totals since 2003 stand at 444 cases, with 262 deaths.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT044886

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel